

## ALCIDION LIMITED FULL YEAR RESULTS

Alcidion Limited (ASX ALC) ("Alcidion" or "The Company"), a leading health informatics business, has today announced its Appendix 4E – Full Year Financial results for the period ended 30 June 2017.

The Company has been focused on its commercialisation strategy of developing and implementing its core proprietary technology - the Miya platform - across a range of hospital customers in the Australian and international markets. The Company currently has an installed base of 15 large tertiary hospitals around Australia including Footscray, Sunshine, Williamstown, Royal Darwin & Alice Springs Hospitals and is available throughout Tasmania.

The Miya technology platform is a unique, advanced Clinical Information System that processes real-time data for improved healthcare decision support and analytics. Alcidion's technology is designed to consolidate the relevant data from many complex and disparate healthcare technology systems to one place, via mobile and desktop devices, allowing clinicians to identify patient status and risk with greater ease and efficacy.

Alcidion achieved several key milestones in FY17, particularly with advancements in the commercialisation of its core Miya technology and entrance into new sites and markets. Highlights include:

- Awarded its first New Zealand contract, signing MidCentral District Health Board to deploy the Miya platform across public hospital facilities to manage the flow of patient care. The value of this contract to Alcidion is NZ\$1.6 million.
- Secured a \$2.35 million contract with Victorian based Western Health, with an initial term of 3-years and an option to extend for a further 2-years. This was a significant contract for the Company as it was preceded by a Memorandum of Understanding. It represents a successful transition from pilot to a full commercial site as well as Alcidion's ability to successfully execute contract renewal and expansion.
- Moved into the private healthcare space with the execution of two statement of works with the Little Company of Mary Health Care, part of the operators of Calvary. Calvary currently operates 15 public and private hospitals, 17 retirement and aged care facilities and a national network of community care centres across Australia.
- Expanded technology range with the release of Miya Smartpage, a mobile task management solution, based on software that was acquired from a third party. This is a stand-alone cloud based product to address the need for improved clinical collaboration, communication, and tasking of clinical and non-clinical staff (e.g. orderlies). Miya Smartpage will integrate with Miya Patient Flow to provide significant additional benefit in the safe and fast processing of patients through the hospital.

- Completed Best Practice ED Pathology Ordering Solution for NT Health with deployment underway.
- Launched iScheduler, an advanced suite of electronic referral software within the Miya family, to significantly improve the access of patients to outpatient, ambulatory and telehealth services. This software is especially valuable to hospital outpatient departments, GP's, allied health, and community care providers, and provides strong evidence of how technology can be fully integrated, or as a "bolt on", with our existing Miya platform.
- Subsequent to the end of the financial year, announced the appointment of two new Non-Executive Directors as part of a board renewal process. Mr. Geoff Rohrsheim, a software, services and technology entrepreneur, and Ms. Rebecca Wilson, a highly experienced investor relations and corporate advisor, were appointed in July.

### Financial Result

- Revenue from ordinary activities was \$3.46 million, down 14% from \$4.02 million in FY2016, due to delays in buying cycles and contract signing, as well as the retirement of the Remedy Solution product with Australian Unity.
- Net loss after tax was \$2.06 million, noting extraordinary expenses of \$648,000 related to the issue of options, which was an improvement of 19% on the previous year. Taking this into consideration, the underlying loss was \$1.38M. While the improvement in Alcidion's net loss position is attributed to the impact of listing expenses incurred in FY2016, it also included product investment into Alcidion's cloud based platform and lower costs associated with standardised Miya product modules. As these platforms are increasingly launched, Alcidion expects to see greater cost efficiency and demand for more established product offerings.
- Cash at hand at 30 June 2017 was \$5.331 million (\$5.645 million in FY16).

### Outlook and Market Conditions

Alcidion has a clear focus on sales and marketing execution, with a plan to capture opportunities in Australian and international markets through organic sales channels and M&A activity.

Alcidion's technology has been thoughtfully designed to increase clinical and care team productivity, as well as to support clients in achieving faster, safer, and more effective patient care; use of the technology decreases misdiagnoses and mistakes made in medicine, improving patient experience and potentially saving lives. It is evident that the global population is aging, and health care budgets face unprecedented demands. Driven by requirements to improve efficiency and reduce costs, governments around the world are beginning to allocate greater concentration and resources towards digital health technologies. Additionally, at the hospital level, new clinical guidelines have been introduced to better utilise pathology tests, improve patient flow throughout hospitals and minimise prolonged hospital stays due to errors or missing patient information.

Within this, Alcidion's Miya technology, with its focus on data consolidation, clinical risk management, efficiency and productivity, is uniquely positioned and well placed to be take a leading role in the new digital health economy.

Transitioning Alcidion's products to the cloud is a significant and strategically important change to the platform that will create exponential scale up opportunities, driven by the adaptability of the products and their ability to provide real time, point of care support. With cloud based delivery, supported with predictive analytics and advanced metrics, Alcidion can emerge in a less competitive market space with a significant presence, create compelling value for customers, and increase the value available from the Company's existing portfolio of products.

In 2018, the Company expects the achievement of several key milestones including further North American market expansion, which now includes Canada. Alcidion has already entered into preliminary discussions with a number of North American Strategic Partners, aimed at reciprocal distribution agreements, and these discussions are progressing well. In parallel, Alcidion will continue to engage additional public and private hospital groups in Australia and NZ.

In commenting on the results, Executive Chairman Ray Blight said: "Alcidion has a competitive position in the digital healthcare market and we are excited by the number of opportunities ahead of us. We are concentrated on both an organic sales process with key sales and marketing hires, as well as an M&A strategy, which we expect will position us well for international expansion and immediate impact on sales revenue in this coming year. "

## Preliminary Final Report for the year ended 30 June 2017

### Overview

1. Alcidion Group Limited (the Group) delivered a FY17 Loss before tax of \$2.039m. However, this figure includes:
  - a. Non-cash expense of \$0.684m relating to option expenses associated with Brian Leedman joining the Alcidion Group Board.
2. Net Cash at Bank at the end of the year was \$5.331m, with minimal debt.

### Unaudited Preliminary Final Report

The financial information provided in the Appendix 4E is based on the preliminary final report which has been prepared in accordance with Australian Accounting Standards.

The financial report for the year ended 30 June 2017 is in the process of being audited and Alcidion Group Limited will release audited financial statements on/or before 30 September 2017.

### Parent Entity

The ultimate Australian parent entity and the ultimate parent of the Consolidated Entity is Alcidion Group Limited and the details of its subsidiary is as under:

	COUNTRY OF INCORPORATION	CLASS OF SHARES	2017 %	2016 %
Alcidion Corporation Pty Ltd	Australia	Fully paid	100	100

## Details of the reporting period

This preliminary Financial Report under ASX listing rule 4.3A covers Alcidion Group Limited and its controlled entities. Except where stated otherwise, all figures relate to the year ended 30 June 2017 and the previous corresponding period to the year ended 30 June 2016.

## Results for announcement to the market

	Consolidated 2017	Consolidated 2016	Change
Revenue	3,458,112	4,024,964	(14%)
Net loss after tax	(2,060,980)	(2,544,717)	19%
Underlying loss before tax *	(1,355,106)	(1,417,817)	4%
Basic earnings per share (cents)	(0.34)	(0.63)	46%
Diluted earnings per share (cents)	(0.34)	(0.63)	46%

\* The underlying loss before tax is a non-IFRS measure used to present the ongoing activities of the Group. It excludes the Share-based payment expense of \$684,000 in 2017 and corporate restructure / RTO expense of \$1,107,175 in 2016.

## Dividends per security

No dividends were paid or proposed for the current or previous corresponding period. On 31 August 2017, the Directors resolved not to declare an interim or final dividend for the year ended 30 June 2017.

	2017 Cents	2016 Cents	Change
Interim dividend	Nil	Nil	-
Final dividend	Nil	Nil	-

## Net tangible assets per security

	Consolidated 2017	Consolidated 2016
Net assets	5,422,559	6,574,539
less Intangible assets	(78,804)	(102,875)
Net tangible assets	5,343,755	6,471,664
Ordinary shares	607,779,957	602,779,957
Net tangible assets per security – book value	\$0.009	\$0.011

## Entities over which control has been gained or lost

The Group has not obtained or lost control over any entities during the year ended 30 June 2017.

## Details of associates and joint ventures

The Group does not have any associates or joint ventures.

## Commentary on the results for the period

Refer to Preliminary Final Report for year ended 30 June 2017.

## Audit

This report is unaudited however the preliminary final report is based on the consolidated financial statements which are in the process of being audited by the company's auditor, William Buck.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND  
OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 30 JUNE 2017

	<b>CONSOLIDATED UNAUDITED 2017</b>	<b>CONSOLIDATED AUDITED 2016</b>
	\$	\$
<b>Continuing operations</b>		
Revenue	3,458,112	4,024,964
Interest income	99,776	59,627
Other income	2,628	44,654
Cost of sale of goods	(1,181,042)	(1,627,329)
Audit fees	(47,546)	(55,681)
Listing Expense	-	(1,107,175)
Depreciation and amortisation expense	(54,573)	(72,218)
Directors and employee benefits expense	(3,054,541)	(2,703,750)
Finance costs	-	(6,807)
Legal fees	(141,390)	(105,606)
Marketing expense	(122,185)	(123,809)
Operations and administration expense	(748,875)	(559,785)
Other expenses from ordinary activities	(249,470)	(292,077)
<b>Loss before income tax expense</b>	<b>(2,039,106)</b>	<b>(2,524,992)</b>
Income tax expense	21,874	19,725
<b>Loss after tax from continuing operations</b>	<b>(2,060,980)</b>	<b>(2,544,717)</b>
<b>Total comprehensive loss for the year</b>	<b>(2,060,980)</b>	<b>(2,544,717)</b>
<b>(Loss) Per Share</b>		
Basic and diluted loss per share (cents)	(0.34)	(0.63)

The Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes, which form an integral part of the unaudited preliminary final report.

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

**AS AT 30 JUNE 2017**

	<b>CONSOLIDATED UNAUDITED 2017 \$</b>	<b>CONSOLIDATED AUDITED 2016 \$</b>
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	5,331,263	5,645,357
Trade and other receivables	1,238,613	2,122,173
Other financial assets	73,536	59,374
Total current assets	6,643,412	7,826,904
<b>Non-current assets</b>		
Property, plant and equipment	97,812	137,818
Deferred tax assets	74,437	97,804
Intangible assets and goodwill	4,367	5,071
Other Assets	11,263	-
Total non-current assets	187,879	240,693
<b>Total assets</b>	<b>6,831,291</b>	<b>8,067,597</b>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Trade and other payables	399,068	370,638
Borrowings	-	5,104
Provisions	163,310	202,294
Other	812,954	866,722
Total current liabilities	1,375,332	1,444,758
<b>Non-current liabilities</b>		
Provisions	33,400	48,300
Total non-current liabilities	33,400	48,300
<b>Total liabilities</b>	<b>1,408,732</b>	<b>1,493,058</b>
<b>Net assets</b>	<b>5,422,559</b>	<b>6,574,539</b>
<b>Equity</b>		
Issued capital	10,793,683	10,568,683
Reserves	684,000	-
Accumulated Losses	(6,055,124)	(3,994,144)
<b>Total equity</b>	<b>5,422,559</b>	<b>6,574,539</b>

The Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes, which form an integral part of the unaudited preliminary financial report.



**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 30 JUNE 2017**

	CONSOLIDATED UNAUDITED 2017 \$	CONSOLIDATED AUDITED 2016 \$
<b>Cash flows from operating activities</b>		
Receipts from customers & R&D Rebate received	4,345,205	3,209,630
Payments to suppliers and employees	(4,964,404)	(5,891,692)
Interest received	99,776	59,627
Finance costs	-	(6,807)
<b>Net cash (outflows) from operating activities</b>	<b>(519,423)</b>	<b>(2,629,242)</b>
<b>Cash flows from investing activities</b>		
Cash received from reverse acquisition	-	5,332,057
Payments for property, plant and equipment	(14,567)	(19,220)
<b>Net cash inflows/(outflows) from investing activities</b>	<b>(14,567)</b>	<b>5,312,837</b>
<b>Cash flows from financing activities</b>		
Proceeds from issue of shares	225,000	682,500
Repayments of borrowings	(5,104)	(41,992)
<b>Net cash inflows from financing activities</b>	<b>219,896</b>	<b>640,508</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(314,094)</b>	<b>3,324,103</b>
Cash and cash equivalents at the beginning of the year	5,645,357	2,321,254
<b>Cash and cash equivalents at the end of the year</b>	<b>5,331,263</b>	<b>5,645,357</b>

The Consolidated Statement of Cash Flow should be read in conjunction with the accompanying notes, which form an integral part of the unaudited preliminary final report.

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 30 JUNE 2017**

	Issued capital	Reserves	Accumulated losses	Total equity
	\$	\$	\$	\$
<b>AUDITED</b>				
Balance as at 1 July 2015	2,100,004	-	(1,449,427)	650,577
Loss for the year	-	-	(2,544,717)	(2,544,717)
Other comprehensive income, net of income tax	-	-	-	-
<b>Total comprehensive loss for the year</b>	-	-	(2,544,717)	(2,544,717)
Shares issued during the year	2,182,500	-	-	2,182,500
Share-based payments – reverse acquisition	6,286,179	-	-	6,286,179
<b>Balance as at 30 June 2016</b>	<b>10,568,683</b>	<b>-</b>	<b>(3,994,144)</b>	<b>6,574,539</b>
<b>UNAUDITED</b>				
Balance as at 1 July 2016	10,568,683	-	(3,994,144)	6,574,539
Loss for the year	-	-	(2,060,980)	(2,060,980)
Other comprehensive income, net of income tax	-	-	-	-
<b>Total comprehensive loss for the year</b>	-	-	(2,060,980)	(2,060,980)
Shares issued during the year	225,000	-	-	225,000
Options issued during the year	-	684,000	-	684,000
<b>Balance as at 30 June 2017</b>	<b>10,793,683</b>	<b>684,000</b>	<b>(6,055,124)</b>	<b>5,422,559</b>

## Notes to The Preliminary Final Report

### General information

Alcidion Group Limited (the Company and controlled entity) is a limited company incorporated in Australia. The core of Alcidion's business model is to create intellectual property in the form of Clinical Decision Support Systems (CDSS) software developed to improve the quality of care for all patients and improve the productivity of clinicians and care teams.

The Company's software is bundled with other technologies and services to create complete clinical and business solutions for health care providers. In short, Alcidion builds, sells, delivers, runs and supports solutions for health care provider organisations around the Australia and New Zealand.

### Statement of significant accounting policies

These unaudited preliminary consolidated financial statements are concise financial statements which have been prepared in accordance with the Corporations Act 2001 (Cth), Australian Accounting Standards and Interpretations, and comply with other requirements of the law.

The unaudited preliminary financial statements comprise the consolidated financial statements of the Company and its controlled entity (collectively the Group). The unaudited preliminary financial statements and other information included in this concise financial report are derived from, and are consistent with, the full financial report of the Group.

The unaudited preliminary financial statements were authorised for issue by the directors on 31 August 2017.

### Basis of preparation

The financial statements comprise the unaudited preliminary consolidated financial statements of the Group. For the purposes of preparing the unaudited preliminary consolidated financial statements, the Company is a for profit entity. Material accounting policies adopted in the preparation of these unaudited preliminary financial statements are presented below. They have been consistently applied unless otherwise stated.

These condensed consolidated financial statements represent those of Alcidion Group Limited and controlled entities (the "consolidated group" or "group").

These condensed consolidated financial statements are in the process of being audited by the company's auditor, William Buck.

The financial statements have been prepared in accordance with the recognition and measurement requirements of Australian Accounting Standards and Interpretations as issued by the Australian Accounting Standards Board and International Financial Reporting Standards as issued by the International Accounting Standards Board.

## Use of Estimates and Judgements

The Directors evaluate estimates and judgements incorporated into the condensed financial statements based on historical knowledge and best available current information. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions are recognised in the period in which the estimate is revised if it affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

## Financial position

The unaudited preliminary consolidated financial statements have been prepared on an accruals basis and are based on historical costs modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. Historical cost is generally based on the fair values of the consideration given in exchange for goods and services.

The unaudited preliminary financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the ordinary course of business.

The Group has incurred a net loss after tax for the year ended 30 June 2017 of \$2,060,980 (2016: \$2,544,717 loss), and a net cash outflow from operations of \$519,423 (2016: outflow of \$2,629,242). At 30 June 2017, the Group has net current assets of \$5,268,080 (2016: \$ 6,382,146 net current assets/liabilities) and net equity of \$5,407,411 (2016: \$6,574,539).

Based on a cash flow forecast, the Group has sufficient working capital to fund its mandatory obligations for the period ending 12 months from the date of this report. Should the Group be unable to generate sufficient funds from its operations or it is unable to raise sufficient capital, the planned operations and software development may have to be amended. The Board is confident in securing sufficient additional capital to fund the operations of the Group. The Directors consider the going concern basis of preparation to be appropriate based on forecast cash flows and confidence in raising additional funds.

### Use of estimates and judgments

The preparation of consolidated financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. These estimates and associated assumptions are based on historical experience and various factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

### Comparative figures

Where required by AASBs comparative figures have been adjusted to conform with changes in presentation for the current financial year.

Where the Group retrospectively applies an accounting policy, makes a retrospective restatement or reclassifies items in its financial statements, an additional (third) statement of financial position as at the beginning of the preceding period in addition to the minimum comparative financial statements is presented.

### Principles of consolidation

As at reporting date, the assets and liabilities of all controlled entities have been incorporated into the unaudited preliminary consolidated financial statements as well as their results for the year then ended. Where controlled entities have entered (left) the Consolidated Group during the year, their operating results have been included (excluded) from the date control was obtained (ceased).

## Business combinations

Business combinations are accounted for using the acquisition method as at the acquisition date, which is the date on which control is transferred to the Group. Control exists when the Group is exposed to variable returns from another entity and has the ability to affect those returns through its power over the entity.

The Group measures goodwill at the acquisition date as:

- the fair value of the consideration transferred; plus
- the recognised amount of any non-controlling interests in the acquire; plus
- if the business combination is achieved in stages, the fair value of the existing equity interest in the acquiree;

less

- the net recognised amount of the identifiable assets acquired and liabilities assumed.

When the excess is negative, a bargain purchase gain is recognised immediately in profit or loss.

The consideration transferred does not include amounts related to settlement of pre-existing relationships. Such amounts are generally recognised in profit or loss.

Costs related to the acquisition, other than those associated with the issue of debt or equity securities, that the Group incurs in connection with a business combination are expensed as incurred.

Any contingent consideration payable is recognised at fair value at the acquisition date. If the contingent consideration is classified as equity, it is not remeasured and settlement is accounted for within equity. Otherwise, subsequent changes to the fair value of the contingent consideration are recognised in profit or loss.

### Subsidiaries

Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the unaudited preliminary consolidated financial statements from the date that control commences until the date that control ceases.

The accounting policies of subsidiaries have been changed when necessary to align them with the policies adopted by the Group. Losses applicable to the non-controlling interests in a subsidiary are allocated to the non-controlling interests even if doing so causes the non-controlling interests to have a deficit balance.

### Subsequent Events

The Directors are not aware of any significant events since the end of the financial year that have or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in subsequent financial periods.

### Share Capital

During the year the Company's share base changed:

	<b>2017</b>	<b>2016</b>
Initial Number of Shares issued	602,779,957	138,263,828
Capital Raising	-	64,516,129
Acquisition through Share based Payment	-	400,000,000
Issue through Share based Payment	5,000,000	-
Total Number Shares Issued at 30 June 2017	607,779,957	602,779,957

Number of restricted shares for a period of up to 24 months after the 29th February 2016 is 267,352,218 Shares. 2,927,641 are restricted for 12 months and 264,424,576 are restricted for 24 months.

### Twenty largest registered holders – ordinary shares

Rank	Name	Units	% of Units
1.	Prof. Malcolm Pradhan	134,582,403	22.14%
2.	Mr Raymond Blight	94,828,781	15.60%
3.	BSPE Medical Technology Pty Ltd	84,864,273	13.96%
4.	Allure Capital Pty Ltd	16,717,243	2.75%
5.	Mr Duncan Robert Craig	3,873,101	0.64%
6.	Mrs Sofiah Valibhoy	3,726,236	0.61%
7.	WALSH PRESTIGE PTY LTD	3,500,001	0.58%
8.	MR PHILLIP JOHN COULSON	3,177,329	0.52%
9.	WALANI PTY LTD	3,177,329	0.52%
10.	WILK HOLDINGS PTY LTD	3,000,000	0.49%
11.	ZIGSUPER PTY LTD	3,000,000	0.49%
12.	MR JACOB OSCAR COULSON	2,541,863	0.42%
13.	ALLURE CAPITAL PTY LTD	2,458,828	0.40%
14.	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	2,370,933	0.39%
15.	YAVERN CREEK HOLDINGS PTY LTD	2,350,000	0.39%
16.	MUHLBAUER INVESTMENTS PTY LTD	2,244,504	0.37%
17.	MS ROBYN GAILE MORRIS	2,222,222	0.37%
18.	PULKO INVESTMENTS PTY LTD >	2,200,000	0.36%
19.	MR DENNIS PAUL O'FARRELL + MRS OKSANA O'FARRELL	2,076,892	0.34%
20.	ALLEKIAN EXCHANGE PTY LTD	2,000,000	0.33%

Shareholder data as of 18/08/2017.



## Corporate Directory

### Current Directors (Alcidion Group Limited)

Name	Position	Date of Appointment
Mr. Ray Blight	Executive Chairman	22/02/2016
Prof. Malcolm Pradhan	Executive Director	22/02/2016
Mr. Nick Dignam	Non-Executive Director	22/02/2016
Mr. Geoff Rohrsheim	Non-Executive Director	01/08/2017
Ms. Rebecca Wilson	Non-Executive Director	01/08/2017

### Previous Directors

Name	Position	Date of Resignation
Mr. Josh Puckridge	Non-Executive Director	29/11/2016
Mr. Nathan Buzza	Executive Director	31/07/2017
Mr. Brian Leedman	Non-Executive Director	31/07/2017

### Registered office and principal place of office

c/- BDO Australia (Adelaide)  
Level 7, 420 King William Street  
Adelaide 5000

Principal place of office  
Level 2, 40 Greenhill Road,  
Wayville SA 5034

☎ +61 8 6489 1600

📠 +61 8 6489 1601

### Web Site

[www.alcidion.com](http://www.alcidion.com)

### Auditors

William Buck  
Level 6, 211 Victoria Square  
Adelaide SA 5000  
☎ +61 8 8409 4333  
📠 +61 8 8409 4499

### Accountants

BDO  
Level 7, 420 King William Street  
Adelaide SA 5000  
Australia  
☎ +61 8 7324 6000  
📠 +61 8 7324 61

**Bankers**

Commonwealth Bank  
Business Banking SME  
Level 2, 100 King William Street  
Adelaide SA 5000  
Australia  
☎ + 61 8 8111 0664  
📠 +1300 522 329

**Solicitors**

Kain Corporate + Commercial Lawyers  
315 Wakefield Street  
Adelaide SA 5000  
Australia  
☎ +61 8 7220 0931  
📠 +61 8 7220 0911

**Stock Exchange**

Australian Securities Exchange Limited  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000  
Australia

ASX Code: ALC

**Company Secretary**

Mr. Duncan Robert Craig

**Registers of securities**

Computershare Investor Services Pty Ltd  
Level 5, 115 Grenfell Street,  
Adelaide SA 5000

### About Alcidion

Alcidion Group Limited (ASX:ALC) is a leading provider of intelligent informatics for high performance healthcare that empowers clinicians with decision support tools to ensure the highest quality of care for their patients. By providing clinicians with decision support tools and making recommendations about patient care, patient flow and patient safety, organisational efficiency may be optimised and key clinical risks eliminated.

Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine & Electronic Smartforms.

### Want More Information ?

To learn more about Alcidion solutions, contact your Alcidion representative, visit our website at [www.alcidion.com](http://www.alcidion.com) or call us at 1800 767 873.



**ALCIDION**

[www.alcidion.com](http://www.alcidion.com)  
[sales@alcidion.com](mailto:sales@alcidion.com)  
1800 767 873

2/40 Greenhill Road